A
ACURX PHARMACEUTICALS LLC
NASDAQ: ACXP (Acurx Pharmaceuticals, Inc.)
Last update: 2 hours ago0.500
0.01 (2.35%)
| Previous Close | 0.489 |
| Open | 0.481 |
| Volume | 1,652,996 |
| Avg. Volume (3M) | 6,383,403 |
| Market Cap | 11,740,800 |
| Price / Book | 4.90 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -0.700 |
| Current Ratio (MRQ) | 1.93 |
| Operating Cash Flow (TTM) | -9.37 M |
| Levered Free Cash Flow (TTM) | -4.87 M |
| Return on Assets (TTM) | -106.68% |
| Return on Equity (TTM) | -285.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Acurx Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
0.6
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.95% |
| % Held by Institutions | 17.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Prospect Financial Services Llc | 31 Mar 2025 | 366,576 |
| Nbc Securities, Inc. | 31 Mar 2025 | 30,000 |
| Semmax Financial Advisors Inc. | 31 Mar 2025 | 5,640 |
| 52 Weeks Range | ||
| Median | 8.00 (1,500.00%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 May 2025 | 8.00 (1,500.00%) | Buy | 0.373 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |